Last updated: February 15, 2026
What Is the Development Status of Buparlisib?
Buparlisib (also known as BKM120) is an oral pan-PI3K inhibitor initially developed by Novartis. Its development center focused on oncology, particularly in breast cancer, glioblastoma, and other solid tumors. As of 2023, development of buparlisib has largely halted in many indications due to safety concerns and mixed efficacy results.
Clinical Trial Progress
- Early-Stage Trials: Novartis conducted Phase 1 and 2 trials to evaluate buparlisib's tolerability, pharmacokinetics, and preliminary efficacy.
- Key Phase 2 Studies:
- Breast cancer: Multiple trials combined buparlisib with endocrine therapy, showing some activity but with significant adverse effects.
- Glioblastoma: Trials showed limited benefit.
- Phase 3 Trials: Novartis initiated larger studies in breast cancer (e.g., BELLE-4) but terminated several programs due to lack of sufficient efficacy and safety issues.
Regulatory Status
- FDA: Buparlisib has not received approval. The company announced suspension of ongoing Phase 3 trials in 2017.
- EMA: No regulatory approval granted; development discontinued in major markets.
Current Development Focus
- There is no active clinical development of buparlisib in late-stage trials. Novartis refocused efforts toward other cancer therapeutics.
What Are Market Projections for Buparlisib?
The failure of buparlisib in late-stage clinical trials limits its near-term market potential. The drug is unlikely to regain development momentum without new efficacy or safety data.
Market Landscape
- PI3K Inhibitors in Oncology: The class includes drugs like alpelisib (Novartis) and copanlisib (Bayer).
- Market Size (2022): The PI3K inhibitor market generated approximately $1.4 billion.
- Competitive Advantage: Buparlisib's pan-PI3K inhibition posed risks of adverse effects like hyperglycemia, limiting its clinical utility compared to more selective agents.
Projected Market Impact
- Short Term (1-3 years): Minimal; buparlisib will not contribute to sales outside early exploratory research or academic settings.
- Medium to Long Term (4-10 years): Unlikely to re-emerge unless Pfizer or other developers acquire rights and demonstrate renewed efficacy with improved safety profiles.
Implications for Investment and R&D
- R&D budgets are likely diverted to other PI3K inhibitors with better safety profiles or entirely different therapeutic targets.
- No significant licensing or partnership activity expected for buparlisib given its clinical failure history.
What Are the Key Challenges and Opportunities?
Challenges
- Safety profile issues due to pan-PI3K inhibition leading to adverse effects such as hyperglycemia, rash, and mood disorders.
- Limited efficacy data compared to more selective PI3K inhibitors, which have achieved regulatory approval.
- The strategic shift of developers away from non-selective inhibitors reduces chances of revival.
Opportunities
- Academic research utilizing buparlisib as a tool compound or for understanding PI3K pathway biology.
- Potential repurposing for non-oncology indications where PI3K plays a role, subject to novel safety strategies.
- Combination therapy exploration in specific niches where other drugs fail, although this area appears limited given past trial outcomes.
What Is the Potential Future Trajectory for Buparlisib?
Without renewed clinical development efforts, buparlisib’s market prospects remain bleak. The drug’s failure in phase 3 trials reduces its attractiveness for re-entry into clinical studies. Industry focus migrates toward isoform-specific inhibitors with improved safety profiles.
Future Significance
- Limited to research tool status unless new proprietary data emerge.
- Strategic value in understanding PI3K pathway dynamics rather than commercial viability.
Key Takeaways
- Buparlisib has not advanced past early-phase clinical trials due to safety concerns and limited efficacy.
- No regulatory approval has been obtained; ongoing development has been suspended since 2017.
- The PI3K inhibitor market continues to grow, but buparlisib’s share is negligible.
- Development of more selective PI3K inhibitors circumvents the safety issues faced by buparlisib.
- Academic use of buparlisib persists, but its commercial future is minimal without new clinical evidence.
FAQs
Q1: Has buparlisib received any regulatory approval?
No, buparlisib has not received approval from FDA or EMA.
Q2: Are there ongoing clinical trials involving buparlisib?
No, all late-stage trials have been discontinued since 2017.
Q3: What are the main safety concerns with buparlisib?
Hyperglycemia, rash, mood disorders, and other adverse effects associated with pan-PI3K inhibition.
Q4: How does the market for PI3K inhibitors look currently?
The market is estimated at $1.4 billion in 2022, dominated by selective inhibitors like alpelisib.
Q5: Could buparlisib be repurposed for non-cancer indications?
Potentially, but no substantial development or interest has been reported to date.
Sources
- Novartis. "Buparlisib (BKM120): Development and Clinical Trials." 2022.
- ClinicalTrials.gov. "Buparlisib Clinical Trial Database." Accessed 2023.
- MarketWatch. "PI3K Inhibitors Market Overview." 2022.
- EMA. "European Medicines Agency Approvals." 2023.
- FDA. "Approved Drugs and Discontinued Programs." 2023.
